December 4th 2023
Shortages are growing because of disruption caused natural disasters and ingredient supply issues, as well as increased demand for certain drugs.
FDA Assigns Priority Review for Elacestrant in Metastatic Breast Cancer
August 11th 2022If approved, elacestrant would be the first oral selective estrogen receptor degrader (SERD) as a second- or third-line treatment for patients with ER+/HER2- advanced or metastatic breast cancer. The PDUFA date is Feb. 17, 2023.